Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

The Gilead subsidiary company Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately-held biotechnology company developing in vivo CAR therapeutics, for $350 ...

Kite, a Gilead Company, has agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics.

What: Interius BioTherapeutics is a Philadelphia-based preclinical stage biotechnology company initially focused on treating hematologic malignancies by leveraging its novel gene delivery platform ...